



MEN

FIRST CANCER SITE
PHARYNXPHARYNX
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

FARINGE
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
SECOND CANCER SITE			O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND PHARYNX	937	2.13	1296	2.80	359	15.26	154	1.67	479	2.37	220	2.23	84	1.78	17.55	27.79
HEAD AND NECK	93	4.14	233	9.80	140	106.72	15	2.91	53	4.91	17	3.67	8	4.23	2.49	6.98
ORAL CAVITY	56	10.49	101	17.89	45	146.05	9	7.41	33	12.88	10	9.04	4	8.78	1.79	3.18
PHARYNX	6	1.16	6	1.10	0	0.00	1	0.84	3	1.20	1	0.95	1	2.38	0.03	0.02
LARYNX	31	2.59	126	9.96	95	135.35	5	1.82	17	2.97	6	2.44	3	2.96	0.67	3.78
OESOPHAGUS	96	18.05	169	30.07	73	240.87	18	15.18	49	19.50	23	20.47	6	12.13	3.20	5.45
STOMACH	40	1.59	43	1.61	3	2.06	6	1.07	17	1.46	9	1.65	8	3.14	0.52	0.55
COLON RECTUM	83	1.41	90	1.45	7	2.25	13	1.07	36	1.33	24	1.79	10	1.54	0.85	0.93
COLON	56	1.40	59	1.40	3	1.44	8	0.98	24	1.32	19	2.08	5	1.11	0.56	0.56
RECTUM	27	1.42	31	1.55	4	3.89	5	1.25	12	1.37	5	1.18	5	2.51	0.28	0.37
LIVER	41	2.25	54	2.81	13	13.29	10	2.61	21	2.48	6	1.49	4	2.09	0.80	1.16
GALLBLADDER	2	0.47	2	0.45	0	0.00	0	0.00	1	0.52	1	1.05	0	0.00	-0.08	-0.08
PANCREAS	19	1.61	19	1.53	0	0.00	3	1.22	9	1.67	3	1.14	4	3.11	0.25	0.22
LUNG	318	3.99	395	4.69	77	17.23	51	2.93	175	4.71	70	4.06	22	2.77	8.41	10.37
SKIN MELANOMA	5	0.71	6	0.81	1	2.77	1	0.69	2	0.61	0	0.00	2	2.72	-0.07	-0.05
MESOTHELIOMA	2	0.80	2	0.76	0	0.00	0	0.00	2	1.74	0	0.00	0	0.00	-0.02	-0.02
KAPOSI SARCOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
SOFT TISSUE	2	1.24	2	1.18	0	0.00	0	0.00	1	1.33	1	2.82	0	0.00	0.01	0.01
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
BREAST	1	1.04	1	0.99	0	0.00	0	0.00	1	2.25	0	0.00	0	0.00	0.00	0.00
PROSTATE	77	0.93	81	0.93	4	1.00	16	1.01	30	0.81	25	1.26	6	0.59	-0.21	-0.20
TESTIS	1	1.34	1	1.26	0	0.00	0	0.00	1	2.70	0	0.00	0	0.00	0.01	0.01
KIDNEY AND RENAL PELVIS	15	1.00	24	1.52	9	11.38	4	1.28	6	0.86	3	0.90	2	1.29	0.00	0.27
BLADDER AND URINARY TRACT	60	1.26	64	1.27	4	1.55	7	0.70	32	1.46	16	1.50	5	0.98	0.43	0.46
URINARY BLADDER	58	1.27	62	1.29	4	1.62	7	0.73	32	1.52	14	1.37	5	1.03	0.43	0.46
URINARY TRACT	2	0.99	2	0.94	0	0.00	0	0.00	0	0.00	2	4.46	0	0.00	0.00	0.00
BRAIN AND CENTRAL NERVOUS SYSTEM	5	0.88	5	0.84	0	0.00	1	0.81	0	0.00	3	2.45	1	1.86	-0.02	-0.03
THYROID	4	1.58	13	4.88	9	68.66	3	5.68	1	0.84	0	0.00	0	0.00	0.05	0.35
HODGKIN LYMPHOMA	2	1.82	2	1.72	0	0.00	0	0.00	2	3.80	0	0.00	0	0.00	0.03	0.03
NON-HODGKIN LYMPHOMA	14	1.06	20	1.44	6	8.53	1	0.36	10	1.64	0	0.00	3	2.21	0.03	0.20
MYELOMA	4	0.72	5	0.85	1	3.32	1	0.85	1	0.39	2	1.60	0	0.00	-0.06	-0.03
LEUKAEMIAS	19	1.97	21	2.06	2	3.75	3	1.45	8	1.80	5	2.35	3	2.97	0.33	0.36
LYMPHOID LEUKAEMIAS	4	0.84	6	1.19	2	7.53	1	0.97	1	0.45	2	1.91	0	0.00	-0.03	0.03
MYELOID LEUKAEMIAS	14	3.28	14	3.11	0	0.00	2	2.22	6	3.08	3	3.15	3	6.45	0.34	0.32
OTHER LEUKAEMIAS	1	1.70	1	1.60	0	0.00	0	0.00	1	3.71	0	0.00	0	0.00	0.01	0.01
OTHER AND ILL DEFINED SITES	40	1.87	50	2.22	10	8.53	2	0.44	24	2.46	13	2.74	1	0.43	0.66	0.92

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE
PHARYNXPHARYNX
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

FARINGE
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months		
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR		
SECOND CANCER SITE			O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR		
ALL SITES, BUT SKIN AND PHARYNX	157	8572	157	1.99	201	2.45	44	12.80	24	1.78	86	2.51	31	1.58	16	1.41	9.13	13.26
HEAD AND NECK	15	8572	15	14.05	32	28.72	17	364.74	3	16.28	6	12.82	5	18.98	1	6.59	1.63	3.45
ORAL CAVITY	11	8572	11	20.49	18	32.14	7	302.08	2	22.23	5	21.62	4	29.59	0	0.00	1.22	1.95
PHARYNX	0	8572	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
LARYNX	4	8572	4	14.99	14	50.32	10	875.82	1	21.79	1	8.45	1	15.23	1	27.09	0.44	1.53
OESOPHAGUS	9	8572	9	25.58	11	29.93	2	126.92	0	0.00	7	46.87	2	22.45	0	0.00	1.01	1.19
STOMACH	10	8572	10	2.53	11	2.65	1	5.25	2	2.87	5	2.95	1	1.01	2	3.51	0.71	0.77
COLON RECTUM	10	8572	10	0.89	12	1.02	2	4.06	4	2.12	2	0.42	3	1.04	1	0.59	-0.15	0.03
COLON	7	8572	7	0.87	9	1.07	2	5.72	3	2.25	0	0.00	3	1.46	1	0.82	-0.12	0.07
RECTUM	3	8572	3	0.93	3	0.89	0	0.00	1	1.82	2	1.43	0	0.00	0	0.00	-0.03	-0.04
LIVER	5	8572	5	2.75	5	2.64	0	0.00	0	0.00	2	2.60	3	6.41	0	0.00	0.37	0.35
GALLBLADDER	0	8572	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.17	-0.17
PANCREAS	2	8572	2	0.73	2	0.70	0	0.00	0	0.00	2	1.74	0	0.00	0	0.00	-0.09	-0.10
LUNG	35	8572	35	7.23	44	8.73	9	44.71	4	5.06	24	11.63	6	4.86	1	1.33	3.52	4.35
SKIN MELANOMA	0	8572	0	0.00	1	0.59	1	14.48	0	0.00	0	0.00	0	0.00	0	0.00	-0.19	-0.08
MESOTHELIOMA	0	8572	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.02
KAPOSI SARCOMA	0	8572	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
SOFT TISSUE	1	8572	1	2.97	2	5.70	1	68.70	0	0.00	1	6.78	0	0.00	0	0.00	0.08	0.18
BONE	1	8572	1	10.93	1	10.46	0	0.00	0	0.00	0	0.00	0	0.00	1	80.90	0.11	0.10
BREAST	26	8572	26	1.15	31	1.32	5	5.11	5	1.27	13	1.30	6	1.09	2	0.65	0.40	0.83
CERVIX UTERI	6	8572	6	5.00	6	4.77	0	0.00	1	4.34	5	9.09	0	0.00	0	0.00	0.56	0.53
CORPUS UTERI	4	8572	4	0.99	4	0.95	0	0.00	1	1.43	1	0.56	0	0.00	2	3.67	0.00	-0.02
OVARY	3	8572	3	1.15	3	1.10	0	0.00	0	0.00	0	0.00	0	0.00	3	8.44	0.04	0.03
KIDNEY AND RENAL PELVIS	4	8572	4	2.13	5	2.55	1	12.80	0	0.00	1	1.24	2	4.19	1	3.48	0.25	0.34
BLADDER AND URINARY TRACT	7	8572	7	2.58	7	2.48	0	0.00	1	2.23	4	3.47	2	2.88	0	0.00	0.50	0.47
URINARY BLADDER	7	8572	7	2.77	7	2.66	0	0.00	1	2.39	4	3.72	2	3.09	0	0.00	0.52	0.49
URINARY TRACT	0	8572	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
BRAIN AND CENTRAL NERVOUS SYSTEM	1	8572	1	0.86	1	0.83	0	0.00	0	0.00	1	1.97	0	0.00	0	0.00	-0.02	-0.02
THYROID	5	8572	5	2.71	6	3.12	1	13.11	2	6.32	1	1.21	0	0.00	2	8.03	0.37	0.46
HODGKIN LYMPHOMA	1	8572	1	4.45	1	4.26	0	0.00	0	0.00	1	9.90	0	0.00	0	0.00	0.09	0.09
NON-HODGKIN LYMPHOMA	3	8572	3	1.03	5	1.64	2	16.12	0	0.00	3	2.38	0	0.00	0	0.00	0.01	0.22
MYELOMA	1	8572	1	0.79	1	0.76	0	0.00	0	0.00	1	1.84	0	0.00	0	0.00	-0.03	-0.04
LEUKAEMIAS	2	8572	2	1.14	2	1.09	0	0.00	0	0.00	2	2.64	0	0.00	0	0.00	0.03	0.02
LYMPHOID LEUKAEMIAS	0	8572	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.09	-0.09
MYELOID LEUKAEMIAS	2	8572	2	2.34	2	2.24	0	0.00	0	0.00	2	5.46	0	0.00	0	0.00	0.13	0.12
OTHER LEUKAEMIAS	0	8572	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
OTHER AND ILL DEFINED SITES	6	8572	6	1.21	8	1.54	2	8.89	1	1.19	4	1.90	1	0.79	0	0.00	0.12	0.31

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio